Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease. / Wesnes, K.; Edgar, C.; Andreasen, N.; Annas, P.; Basun, H.; Lannfelt, L.; Zetterberg, H.; Blennow, K.; Minthon, Lennart.

I: Acta Neurologica Scandinavica, Vol. 122, Nr. 4, 2010, s. 270-277.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

Wesnes, K, Edgar, C, Andreasen, N, Annas, P, Basun, H, Lannfelt, L, Zetterberg, H, Blennow, K & Minthon, L 2010, 'Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease', Acta Neurologica Scandinavica, vol. 122, nr. 4, s. 270-277. https://doi.org/10.1111/j.1600-0404.2009.01309.x

APA

Wesnes, K., Edgar, C., Andreasen, N., Annas, P., Basun, H., Lannfelt, L., Zetterberg, H., Blennow, K., & Minthon, L. (2010). Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease. Acta Neurologica Scandinavica, 122(4), 270-277. https://doi.org/10.1111/j.1600-0404.2009.01309.x

CBE

MLA

Vancouver

Author

Wesnes, K. ; Edgar, C. ; Andreasen, N. ; Annas, P. ; Basun, H. ; Lannfelt, L. ; Zetterberg, H. ; Blennow, K. ; Minthon, Lennart. / Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease. I: Acta Neurologica Scandinavica. 2010 ; Vol. 122, Nr. 4. s. 270-277.

RIS

TY - JOUR

T1 - Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease

AU - Wesnes, K.

AU - Edgar, C.

AU - Andreasen, N.

AU - Annas, P.

AU - Basun, H.

AU - Lannfelt, L.

AU - Zetterberg, H.

AU - Blennow, K.

AU - Minthon, Lennart

PY - 2010

Y1 - 2010

N2 - Objectives - Alzheimer's disease assessment scale-cognitive subscale (ADAS-Cog) has become a standard clinical trials outcome for cognition, but has been recognized as deficient in areas including coverage of cognitive domains, sensitivity and standardization. Computerized test batteries may address some of these issues. The cognitive drug research computerized assessment (CDR) system is validated in Alzheimer's disease (AD). This study was designed to further evaluate validity in relation to ADAS-Cog, mini mental state examination (MMSE) and cerebrospinal fluid (CSF) biomarkers and psychometric properties, in a population of Alzheimer's patients on stable anticholinesterase treatment. Materials and methods - Patients completed cognition assessments, CSF and blood sampling at baseline and 6 months later. Data for 65 patients were evaluated. Results - The CDR system demonstrated good psychometric properties in this population. Measures of psychomotor speed showed possible sensitivity to decline over 6 months. Conclusions - There are a number of methodological problems with current cognition assessment methodology for clinical trials. Computerized measures and in particular millisecond reaction time measures, may address many of these issues.

AB - Objectives - Alzheimer's disease assessment scale-cognitive subscale (ADAS-Cog) has become a standard clinical trials outcome for cognition, but has been recognized as deficient in areas including coverage of cognitive domains, sensitivity and standardization. Computerized test batteries may address some of these issues. The cognitive drug research computerized assessment (CDR) system is validated in Alzheimer's disease (AD). This study was designed to further evaluate validity in relation to ADAS-Cog, mini mental state examination (MMSE) and cerebrospinal fluid (CSF) biomarkers and psychometric properties, in a population of Alzheimer's patients on stable anticholinesterase treatment. Materials and methods - Patients completed cognition assessments, CSF and blood sampling at baseline and 6 months later. Data for 65 patients were evaluated. Results - The CDR system demonstrated good psychometric properties in this population. Measures of psychomotor speed showed possible sensitivity to decline over 6 months. Conclusions - There are a number of methodological problems with current cognition assessment methodology for clinical trials. Computerized measures and in particular millisecond reaction time measures, may address many of these issues.

KW - Alzheimer's disease assessment scale-cognitive subscale

KW - system

KW - cognitive drug research

KW - computerized

KW - cognition

KW - Alzheimer's disease

KW - mini

KW - mental state examination

U2 - 10.1111/j.1600-0404.2009.01309.x

DO - 10.1111/j.1600-0404.2009.01309.x

M3 - Article

C2 - 20047570

VL - 122

SP - 270

EP - 277

JO - Acta Neurologica Scandinavica

JF - Acta Neurologica Scandinavica

SN - 1600-0404

IS - 4

ER -